# AI Drug Discovery

From Bench to Bedside: Isomorphic Labs Targets $2 Billion to Scale AI-Driven Drug Discovery

Isomorphic Labs, a spin-off of Google's DeepMind, is in advanced talks to raise over $2 billion in a funding round led by Thrive Capital. The company aims to leverage its proprietary AI models to revolutionize drug discovery, marking a significant escalation in Big Tech’s expansion into the pharmaceutical sector.